Snapshot: February Highlights
Executive Summary
A selection of articles you might have missed from February 2022, including exclusive interviews and a look at the gene editing pipeline.
You may also be interested in...
Ovid Therapeutics: Seeking Innovation In Epilepsy Treatment
Rising Leader Julia Tsai wants to see Ovid Therapeutics become a market leading epilepsy company that listens to the needs of patients and develops innovative drugs to treat a spectrum of epileptic indications and symptoms.
Synaffix’s Serial Dealmaker On ADC Platform Success And Expanding Into Gene Therapy
Anthony DeBoer, head of business development at Synaffix, joined the company in 2014 and has helped develop a platform technology business model in the antibody drug conjugate space, where Synaffix has become one of the leading technology providers enabling best-in-class therapeutic candidates.
In Vivo's 2023 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fourth edition of In Vivo's Rising Leaders series.